4S,17R-dihydroxy-DHA | 528583-87-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4S,17R-dihydroxy-DHA
• 英文别名: 4S-17R-dihydroxy-docosa-5E,7Z,10Z,13Z,15E,19Z-hexaenoic acid；4S,17R-diHDHA；(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-4,17-dihydroxydocosa-5,7,10,13,15,19-hexaenoic Acid
• CAS: 528583-87-1
• 化学式: C₂₂H₃₂O₄
• 分子量: 360.494
• InChiKey: JKPUWSZSJINVLB-VDOHSOROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4S,17R-dihydroxy-DHA 生成 5,7,10,13,15,19-Docosahexaenoic acid, 4,17,22-trihydroxy-,(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3
• 作为产物：
  描述：

  在 copper/silver activated zinc 、 水 作用下， 以 甲醇 为溶剂， 反应 16.0h， 生成 4S,17R-dihydroxy-DHA
  参考文献：
  名称：

  首次全合成 4(R),17(R)-Resolvin D6 立体异构体，一种有效的神经保护二十二烷酸

  摘要：

  描述了一种新型神经保护 Resolvin D6 对映体 4( R ),17( R )-Resolvin D6 的首次全合成。Resolvin D6 是一种源自二十二碳六烯酸 (DHA, C22:6,  ω -3) 的脂质介质，具有抗炎特性。关键合成特征包括使用 MacMillan 对映选择性有机催化α -醛的氧化结合基于手性池的方法生成手性合成子、1,4-烯炔单元作为关键，以及 ( Z )-选择性Wittig 耦合组装 Resolvin D6 核心碳骨架。

  DOI：

  10.1016/j.tetlet.2022.154091

文献信息

• Resolvins: Biotemplates for therapeutic interventions
  申请人：BRIGHAM AND WOMEN'S HOSPITAL

  公开号：EP2216318A2

  公开（公告）日：2010-08-11

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 resolvins，由膳食中的ω-3 多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）、环氧化酶-II（COX-2）和镇痛剂如阿司匹林（ASA）之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。
• WO2006/78457
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] RESOLVINS: BIOTEMPLATES FOR THERAPEUTIC INTERVENTIONS<br/>[FR] LES RESOLVINES, DES GABARITS BIOLOGIQUES CONVENANT POUR DE NOUVELLES INTERVENTIONS THERAPEUTIQUES
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2004014835A3

  公开（公告）日：2004-04-15
• Use of Docosatrienes, Resolvins and Their Stable Analogs in the Treatment of Airway Diseases and Asthma
  申请人：Serhan N. Charles

  公开号：US20080096961A1

  公开（公告）日：2008-04-24

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
  申请人：SERHAN CHARLES N.

  公开号：US20100016432A1

  公开（公告）日：2010-01-21

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.